Clinical Trial Update: ABT-510 in Treating Patients With Metastatic Melanoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ABT-510 for metastatic melanoma has completed. The Mayo Clinic sponsored the study.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• ABT-510 (ABT-510)

Snippet

Sponsor: Mayo Clinic | Conditions: Melanoma (Skin) | Phase 2 | Status: COMPLETED